Product Description
Foscarnet is a medication used to manage and treat CMV, HSV, and VZV viral infections in AIDS and immunocompromised patients. It is in the antiviral class of drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK556108/)
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | China | Colombia | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Peru | Poland | Portugal | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|